ATXS Breakout Report

Investor Analysis

Please note: Aeterna Zentaris Inc. (ATXS) was acquired by Ceapro Inc. (TSX-V: CZO / OTCQX: CZOIF) in October 2023. As a result, ATXS no longer trades as an independent stock on public exchanges, and its financial results are now consolidated under Ceapro. This summary provides historical context for Aeterna Zentaris's business operations and addresses the implications of its acquisition. Consequently, specific 2025/2026 revenue and earnings projections for ATXS as a standalone entity are not applicable or available. Historically, the stock experienced significant volatility, including a reported gain of 1084.3% since a notable breakout prior to its acquisition.

---

Business Overview

Prior to its acquisition by Ceapro Inc., Aeterna Zentaris Inc. was a biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostic tests in areas of unmet medical need, primarily in endocrinology and oncology. Its flagship commercial product was Macrilen™ (macimorelin), an orally administered ghrelin mimetic approved for the diagnosis of Adult Growth Hormone Deficiency (AGHD) in the United States and Canada. Macimorelin is also marketed as GHRYVELIN™ in Europe. The company aimed to leverage its expertise in peptide-based therapeutics and diagnostic platforms to bring innovative solutions to market.

Key Competitive Moats (Historical)

• Niche Market Leadership: Macimorelin holds a unique position as the first and only FDA and EMA-approved oral diagnostic test for AGHD. This addresses a significant unmet medical need by offering a more patient-friendly and less invasive alternative to traditional intravenous tests, providing a strong competitive advantage in this specialized market segment.
• Regulatory Approvals: The rigorous and costly process of obtaining FDA and EMA approvals for Macimorelin established high regulatory barriers to entry, making it challenging for new competitors to quickly enter the specific AGHD diagnostic market with similar products.
• Specialized Expertise & IP: Aeterna Zentaris possessed specialized research and development capabilities in peptide therapeutics. Intellectual property, including patents surrounding Macimorelin, provided a period of market exclusivity and protection against generic competition.

Revenue and Earnings Growth (2025/2026)

Due to the acquisition of Aeterna Zentaris Inc. by Ceapro Inc. in October 2023, independent revenue and earnings projections for ATXS for 2025 and 2026 are no longer applicable or reported. Aeterna Zentaris's financial performance, including that of Macimorelin, is now integrated into Ceapro Inc.'s consolidated financial statements. Investors interested in the ongoing performance of Macimorelin and Aeterna Zentaris's legacy assets should refer to Ceapro Inc.'s financial disclosures (TSX-V: CZO / OTCQX: CZOIF). As an independent stock, ATXS is delisted, and thus no future standalone financial forecasts are available.

Recent Catalysts

• Acquisition by Ceapro Inc. (October 2023): This was the most significant recent catalyst. The acquisition resulted in the delisting of ATXS common shares and the company becoming a wholly-owned subsidiary of Ceapro. The transaction aimed to create a diversified life sciences company by combining Aeterna Zentaris's commercial products and pipeline with Ceapro's advanced technology and extract products.
• Strategic Review Process: Prior to the acquisition, Aeterna Zentaris had undergone a comprehensive strategic review process to explore various options for enhancing shareholder value, which ultimately culminated in the definitive agreement with Ceapro.
• Commercialization Milestones: Earlier catalysts included milestones related to Macrilen/GHRYVELIN commercialization, such as achieving regulatory approvals in new territories, securing key distribution agreements, and initial product launches in new markets.

Main Risks

• Delisting and Loss of Independent Trading: For historical investors in ATXS, the primary "risk" is that the stock no longer trades independently. This means there is no direct public market for ATXS shares, and its future is entirely integrated into the performance and strategy of Ceapro Inc.
• Integration Risks (for Ceapro): For investors now holding Ceapro shares, risks include the successful integration of Aeterna Zentaris's operations, personnel, and product portfolio into Ceapro's existing structure. Failure to effectively integrate could impact the combined entity's performance.
• Market Adoption & Competition for Macimorelin: While unique, Macimorelin's long-term commercial success, now under Ceapro, remains dependent on continued market adoption rates, physician prescribing habits, and the potential for future competitive diagnostic methods or treatments for AGHD.
• Clinical Development and Regulatory Risks (Legacy Pipeline): Any remaining legacy pipeline assets from Aeterna Zentaris continue to carry inherent biopharmaceutical risks associated with clinical trial outcomes, regulatory approvals, and the significant capital required for drug development.